Treatment of severe odynophagia with long-acting topical nitroglycerin ointment in a patient with acquired immune deficiency syndrome

YOUNG-IN KIM, MD, FRCP, FRED SAIBIL, MD, FRCP, ANITA RACILIS, MD, FRCP

Y-1 KIM, F SAJBIL, A RACHUS, Treatment of severe odynophagia with long-acting topical nitroglycerin ointment in a patient with acquired immune deficiency syndrome. Can J Gastroenterol 1993;7(4):349-352. Odynophagia and dysphagia are common gastrointestinal symptoms experienced by patients with the acquired immune deficiency syndrome (AIDS). These symptoms can significantly decrease food intake and thus worsen nutritional status, leading to significant morbidity in AIDS patients. Esophageal candidiasis is the most common etiological factor associated with odynophagia and dysphagia in AIDS patients, but there are other infectious and malignant causes for these symptoms. Often the standard treatments for these causes are not satisfactory. The authors report a patient with AIDS who had oral candidiasis refractory to oral ketoconazole and severe odynophagia which severely restricted his oral intake. This patient responded dramatically to long-acting nitroglycerin ointment (Nitro-Bid [Hoechst-Roussel Canada, Inc]) while intravenous amphotericin B was being initiated. The authors propose that esophageal spasm may be a significant factor in the genesis of odynophagia and dysphagia in certain patients with AIDS and that smooth muscle relaxants, such as nitroglycerin or calcium channel blockers, may be important adjunctive therapies.

Key Words: Acquired immune deficiency syndrome, Dysphagia, Esophagitis, Nitroglycerin, Odynophagia, Spasm

Traitement de l'odynophagie sévère à l'aide d'onguent de nitroglycerine topique à longue action chez un patient atteint de SIDA

RÉSUMÉ: L'odynophagie et la dysphagie sont des symptômes gastro-intestinaux fréquents chez les patients atteints de SIDA. Ces symptômes peuvent diminuer nettement l'apport alimentaire et ainsi aggraver l'état nutritionnel, ce qui précède...
A 42-year-old homosexual male was diagnosed in 1987 with HIV infection when he presented with oral candidiasis. Subsequently he had three bouts of Pneumocystis carinii pneumonia, Kaposi's sarcoma involving lungs and oral cavity, and herpes-like lesions in the rectal mucosa which were treated with oral acyclovir. The patient had been recently diagnosed with cytomegalovirus retinitis and this was treated with intravenous foscarnet (Astra Pharma Inc) initially, and then 9-(1,3-dihydroxy-2-propoxy methyl) guanine (ganciclovir). The patient had received zidovudine and 2',3'-dideoxynosine in the past but these had been discontinued because of bone marrow suppression and neurotoxicity, respectively. He had recurrent oral candidiasis treated with nystatin mouth wash with no significant improvement.

The patient had been complaining of sharp pain in upper pharynx, and upper and middle chest with each swallow with both liquids and solids (worse with solids), and this had been progressively worsening over the two weeks prior to admission. At admission, he was unable to take anything by mouth and had significant weight loss. He had no pyrosis, regurgitation, nausea, vomiting, abdominal pain, fever or signs of gastrointestinal hemorrhage. His oral candidiasis had been noted to be worse over the week prior to admission and had been treated with oral ketoconazole 200 mg daily for two weeks with no significant improvement. The patient had never had dysphagia or odynophagia in the past and had had no radiological or endoscopic examination of the upper gastrointestinal tract.

On examination, the patient was a cachectic appearing male with Kaposi's sarcoma involving his nose, left neck area and oral cavity. There was severe oral candidiasis but no aphthous ulcers were noted. Other systems were unremarkable. He had severe neutropenia (white blood cell count was 0.9x10^9/L) and absolute neutrophil counts were less than 500x10^9/L; this was thought to be due to ganciclovir which was discontinued.

Because of severe neutropenia, it was felt that risks of aspiration and other infectious complications outweighed potential benefits of diagnostic endoscopy. Intravenous amphotericin B was initiated via a Port-a-cath (Pharmacia) within 12 h of presentation. Long-acting nitroglycerin ointment 1° tid was started for possible esophageal spasm contributing to his odynophagia. The patient had an immediate and dramatic response to the nitroglycerin ointment and his odynophagia subsided so completely within 24 h that he was able to resume his oral intake. The nitroglycerin ointment was continued and amphotericin B was discontinued after five days (oral ketoconazole 200 mg daily was then given).

The patient was discharged on day 9 without odynophagia or dysphagia on ketoconazole 200 mg daily and NitroBID 1° tid.

**DISCUSSION**

Odynophagia and dysphagia are very common in patients with AIDS (1). Although the exact frequencies have not been established since not all patients with esophagitis are symptomatic (15), odynophagia and dysphagia may be the most common symptoms experienced by patients with AIDS (1). These symptoms can significantly decrease food intake, thereby worsening the nutritional status of AIDS patients (1) and are responsible for significant morbidity in these patients.

The most common cause of odynophagia/dysphagia in patients with AIDS is esophageal candidiasis (1). It has been estimated that at King's County Hospital in Brooklyn, New York, more than 75% of patients with AIDS had symptoms of oro-esophageal candidiasis during their hospital course (2). Opportunistic infections of the esophagus with cytomegalovirus (3,4) and herpes simplex virus, both types 1 and 2 (6), are other well known causes for odynophagia/dysphagia in AIDS patients. A recent report from Canadian investigators described oral and esophageal ulcerations in association with electron microscopic evidence of viral particles occurring coincident with HIV seroconversion (7). Other conditions which may cause odynophagia/dysphagia are cryptosporidiosis (8), esophageal lymphoma (9) and oropharyngeal Kaposi's sarcoma (10). It appears that acid-peptic reflux esophagitis may not make a significant contribution to odynophagia/dysphagia in AIDS patients. Interestingly, a recent study (16) has shown that achlorhydria or hypochlorhydria and decreased pepsin in gastric juice may be common in patients with AIDS.

The relationship between oral and esophageal candidiasis is somewhat unsettled. In prospective studies (17-21) of patients with AIDS or AIDS-related complex and oral candidiasis, almost 100% had endoscopic evidence of candidal involvement of the esophagus, regardless of the presence of odynophagia/dysphagia. Therefore, these investigators advocated that a patient with AIDS, odynophagia/dysphagia and oral candidiasis could be presumed to have esophageal candidiasis without radiological or endoscopic confirmation, and the patient could be treated with appropriate antifungal therapy. It was...
suggested that further diagnostic evaluation could be reserved for nonresponders or for patients with clinical and laboratory evidence of an esophageal disorder other than esophageal candidiasis. While oral thrush often predicts concurrent esophagitis, it is clearly established that the absence of thrush does not exclude the possibility of esophageal candidiasis (22,23).

The treatment of odynophagia/dysphagia in AIDS patients depends on the specific etiology. In esophageal candidiasis, nystatin suspension and clotrimazole lozenges are generally considered to be inadequate therapy, even though they may be beneficial for treating oral candidiasis. Ketoconazole has been the mainstay of therapy for esophageal candidiasis (1). This imidazole compound increases fungal membrane permeability by interfering with sterol synthesis (1). Even though oral ketoconazole 200 mg daily is an effective therapy for esophageal candidiasis in patients with immunodeficiency states other than AIDS (11), this dose often is ineffective for eradicating esophageal candidiasis in some patients with AIDS (12). Therefore, a dose of ketoconazole up to 600 mg a day has been suggested (1) to eradicate esophageal candidiasis without causing hepatocellular toxicity. Patients who fail to respond to high dose ketoconazole may respond to the newly developed fluconazole or low dose intravenous amphotericin B.

Herpes esophagitis will respond to acyclovir, although resolution often is followed by relapses. Cytomegalovirus esophagitis has been successfully treated with ganciclovir (13,14), although large, randomized controlled studies with confirmatory endoscopic examinations are lacking.

Reduction of esophageal symptoms is an important goal since it leads to greater comfort, increased oral intake, better nutritional status and ability to take medications. Eradication of these opportunistic infections does not necessarily prolong survival and suppression only may be achieved. The odynophagia, in particular, may have multifactorial causes, such as invasion beyond the mucosa by the organism, inflammatory reactions, and tearing of candidal plaque and associated underlying mucosa by combined mechanical shearing forces of food and peristalsis, as suggested by Gould et al (24). Although it is not proven, we suggest that esophageal spasm may contribute to odynophagia/dysphagia in these AIDS patients.

In uncontrolled trials (25-29), short- and long-acting nitrates reduced symptoms and improved manometric and radiographic patterns in some patients with spastic disorders of smooth muscle segments of the esophagus. These agents are thought to be beneficial because of their relaxant effect on smooth muscle, although the effect on manometric parameters may actually be minimal. Calcium channel blockers, in some anecdotal cases (30-33), have shown potential benefit in the management of spastic disorders of the esophagus. Calcium channel blockers relax the smooth muscle of the esophagus by interfering with calcium uptake by smooth muscle cells which are dependent on intracellular calcium for contraction. However, evidence supporting the uniform efficacy of calcium channel blockers is lacking in controlled studies (34). Successful management of symptoms of esophageal spasm has also been anecdotally reported using psychoactive drugs, including the antidepressant trazodone hydrochloride (35).

The presented patient had severe odynophagia associated with oral candidiasis refractory to oral ketoconazole. The patient also had severe neutropenia which precluded definitive diagnostic endoscopy because of concern for aspiration and infectious complications. Most likely, however, this patient did have severe esophageal candidiasis as suggested by the above discussion. Although opportunistic infections of the esophagus by cytomegalovirus or herpes virus were possibilities, he had been on ganciclovir and acyclovir for some time prior to his presentation. Intravenous amphotericin B was initiated soon after admission but the time interval between the start of amphotericin B and his dramatic response make amphotericin very unlikely as the beneficial agent. Topical nitroglycerin was selected rather than the sublingual or oral forms because of the patient's extreme odynophagia, even on swallowing his saliva. His response to nitroglycerine ointment was immediate and dramatic, suggesting esophageal spasm might have been the most significant factor in his odynophagia.

The patient immediately was able to resume his oral intake for both pleasure and nutritional support, with clear-cut improvement of his quality of life.

CONCLUSIONS

Esophageal spasm may be a significant factor in the odynophagia/dysphagia commonly experienced by AIDS patients. Nitroglycerin—topically, sublingually or orally—may provide rapid amelioration of these symptoms while specific anti-infective treatments are instituted. The symptomatic relief may allow improved nutrient intake in these patients and enhance their general nutritional status and quality of life. Other smooth muscle relaxants, such as calcium channel blockers or psychotropic medications, may have an adjunctive role in the treatment of these esophageal symptoms.

REFERENCES

7. Rabeneck L, Boyko WJ, McLean DM,